10月8日晚间，百济神州发布公告，披露旗下核心BTK抑制剂泽布替尼（商品名"百悦泽"）在美国市场 被诉专利侵权的最新进展：百济神州及艾伯维旗下公司Pharmacyclics公司已向法院提交一份共同协议， 自愿撤回案件，案件已做出终局处理。这意味着，这场历时两年多的跨国专利侵权诉讼案，百济神州获 胜。 尽管双方就上述专利侵权案已经终结，但艾伯维针对百济神州BGB-16673的专利诉讼仍在进行中。2024 年9月，艾伯维提起诉讼，声称百济神州在BTK降解剂研发过程中窃取了艾伯维的商业机密，该诉讼主 要围绕百济神州在研药物BGB-16673。百济神州认为，该诉讼意在阻碍BGB-16673的开发进程。BGB- 16673是一款口服、靶向BTK的在研嵌合式降解激活化合物（CDAC），也是百济神州管线中进展最快 的BTK降解剂，2024年8月27日被FDA授予快速通道认定。 对于这一起诉讼，百济神州表示，无论结果是否对公司有利，对此类申诉进行辩护可能会导致高额成 本，并分散管理层的注意力。如果公司未能抗辩成功，可能导致需要支付经济赔偿以及失去重要的知识 产权并遭受声誉损失。 畅销药的专利保护战 泽布替尼被诉专利侵权，百济 ...

Core Viewpoint - The ongoing patent disputes between BOE and Samsung Display highlight the intensifying competition in the display technology market, particularly in OLED technology, as both companies seek to protect their intellectual property and market share [2][8]. Group 1: Patent Disputes - BOE has filed a request for invalidation against seven patents held by Samsung Display, which were part of a broader patent infringement lawsuit initiated by Samsung in April 2023 [2][4]. - Samsung Display's lawsuits include three patent infringement cases and one trade secret theft case against BOE, with the initial rulings from the U.S. International Trade Commission (ITC) expected to impact the ongoing legal battles [4][7]. - The ITC has issued a preliminary ruling that includes a limited import ban on BOE products found to infringe on Samsung's trade secrets, with a final decision anticipated in November 2023 [7]. Group 2: Legal Proceedings Timeline - Samsung Display filed a patent infringement lawsuit in the Eastern District of Virginia, which includes four patents already deemed valid by the Patent Trial and Appeal Board (PTAB) and one pending decision [8]. - The timeline of the legal proceedings shows that Samsung Display initially filed a lawsuit in the Eastern District of Texas but later withdrew it to refile in Virginia, indicating a strategic shift in their legal approach [8]. - The ongoing legal disputes are expected to continue as both companies are closely monitoring each other's actions to prevent further market encroachment, particularly in the OLED segment [8].

Core Viewpoint - The patent dispute between CATL (宁德时代) and Zhongxin Innovation (中创新航) has seen a significant reversal, with the National Intellectual Property Administration declaring two of CATL's patents invalid [1][2]. Group 1: Patent Dispute Details - Zhongxin Innovation announced on August 3 that the National Intellectual Property Administration ruled two of CATL's patents, related to "lithium-ion batteries" and "positive electrode sheets and batteries," as invalid [1]. - Zhongxin Innovation filed for the invalidation of these patents in June of the previous year, stemming from ongoing patent disputes with CATL [1]. - Since July 2021, CATL has filed lawsuits against Zhongxin Innovation for infringing five patents, claiming a total of 647 million yuan in damages, including 108 million yuan for the two invalidated patents [1]. Group 2: Court Rulings and Appeals - In February of this year, the Fuzhou Intermediate People's Court ruled in favor of CATL, ordering Zhongxin Innovation to pay 57.1 million yuan in damages and cease sales of the infringing products [1]. - Zhongxin Innovation has stated its intention to appeal this ruling to the Supreme People's Court and has not yet paid any compensation to CATL [1][3]. - Zhongxin Innovation also referenced a judicial interpretation from the Supreme People's Court, indicating that if a patent is declared invalid, the court can dismiss related infringement lawsuits [2]. Group 3: Market Position and Financials - As of the latest reports, CATL holds a 36.8% market share in the global power battery market, ranking first, while Zhongxin Innovation ranks sixth with a 4.1% market share [4]. - Both companies are leaders in the power battery industry, with CATL and Zhongxin Innovation ranked first and third, respectively, in the domestic market [4]. - As of August 3, CATL's stock closed at 239.14 yuan, up 1.12%, with a market capitalization of 1.05 trillion yuan, while Zhongxin Innovation's stock closed at 17.82 HKD, down 3.57%, with a market capitalization of approximately 29 billion yuan [4].